Highlights from this issue
Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials
After a long wait, two arrive, one after the other!
Macrolides for yet another chronic airway disease
Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury
Azithromycin for prevention of exacerbations in severe asthma (AZISAST)
GATA2, a novel therapeutic target for RAS-oncogene-addicted NSCLC?
Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD
Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis
Do fast foods cause asthma, rhinoconjunctivitis and eczema? Global findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three
Statins and the risk of interstitial lung disease
Asthma and occupation in the 1958 birth cohort
The relationship between maternal adiposity and infant weight gain, and childhood wheeze and atopy
ERK3 in lung cancer cell invasion
Of flies, mice and men
The role of facemask spirometry in motor neuron disease
Letter to the editors
Azithromycin and severe asthma
The place of comorbidities in ‘COPD control panel’
Response to Vestbo and Rodrigues-Roisin
Authors response. The chronic obstructive pulmonary disease (COPD) control panel
NICE guideline
A rapidly growing lung mass with air crescent formation
Middle airway obstruction—it may be happening under our noses
“Tree in bud” attributable to organising pneumonia